TGF-Œ≤ induces growth suppression in multiple myeloma MM.1S cells via E2F1
Authors: Baimeng Zhang
Xialei Liu
Yuting Wei
Jian Li
Chaonong Cai
Hui Guo
Journal: Oncology letters (2017)
Discipline: CLINICAL MEDICINE
Keywords: E2F1; MM.1S cell line; TGF-Œ≤; cell viability; siRNA.
Affiliations: Department of General Surgery 3, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, P.R. China., Department of Ultrasound, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, P.R. China., Department of Hemodialysis, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, P.R. China.

Abstract:  Transforming growth factor-Œ≤ (TGF-Œ≤) has an important role in multiple target genes and signaling pathways. The E2F family of transcription factors is a group of DNA-binding proteins that are involved in cell-cycle progression, and therefore have a key role in proliferation. The present study demonstrates that inhibition of cell growth by TGF-Œ≤ occurs in the multiple myeloma cell line MM.1S. However, the growth-suppressive effects of TGF-Œ≤ may be reversed by small interfering (si)RNA to reduce the expression of E2F1. TGF-Œ≤1 and E2F1 siRNA were manipulated in MM.1S cells to investigate the association between these genes. FACScan Flow Cytometer, western blot analysis and other methods were adopted to confirm such interrelation. The present data showed that TGF-Œ≤ mediated growth suppression in MM.1S cells, while inducing E2F1 protein expression levels rapidly and transiently. The present data support the hypothesis that E2F1 is a central mediator of TGF-Œ≤-induced growth suppression in MM.1S cells and control of E2F1 may be a downstream event of TGF-Œ≤ action, at least in one multiple myeloma cell line. 

Retracted: No

PubPeer comments:
 Image concerns in this paper were found during a systematic search of papers in Spandidos journals for possible duplicated images. * Red boxes: The  Control lane in the E2F1 panel of Figure 2 looks similar to the  24h TGF-B treatment lane in the E2F1 panel of Figure 4.  , 
 Corrigendum, December 2020: https: www.spandidos-publications.com 10.3892 ol.2020.12344  Subsequently to the publication of this paper, an interested reader drew to the authorsu2019 attention that the u201cControlu201d lane in the E2F1 panel of Fig. 2 appeared to be strikingly similar to the u201c24 hu201d TGF-u03b2 treatment lane in the E2F1 panel of Fig. 4. Although the authors were unable to locate the original raw data to evaluate how the errors in figure compilation had occurred, they were able to repeat these experiments, and thereby could confirm that: i) E2F1 truly may can be down-regulated in the MM1s cell line through siRNA targeting E2F1; and ii) TGF-u03b2 can induce the immediate expression of E2F1 in the MM1s cell line within 24 h. The revised versions of Figs. 2 and 4, containing the new data, are shown opposite. The authors regret the errors that were made in the compilation of the orginal [SIC] figures, and are grateful to the editor of Oncology Letters for allowing them the opportunity to publish a Corrigendum. Furthermore, they apologise to the readership for any inconvenience caused. ,